Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Former Bard execs sentencing

This article was originally published in The Gray Sheet

Executive Summary

Former Bard execs sentencing: Judge Joseph Tauro, U.S. District Court, Boston, schedules Aug. 8 sentencing of three ex-Bard executives convicted in August 1995 of conspiring to defraud FDA ("The Gray Sheet" Aug. 28, 1995, p. 2). The former execs convicted are: Bard group exec VP David Prigmore; John Cvinar, former President of Bard's USCI angioplasty catheter division; and Lee Leichter, former director of regulatory affairs and quality assurance for USCI. Former Bard CEO, George Maloney, and Kenneth Thurston, former director of regulatory affairs for USCI, were acquitted. Charges facing Janice Piasecki, a former supervisor in the regulatory affairs department, were dropped. The three defendants found guilty each face up to five years imprisonment and a fine of $250,000...

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts